adenine has been researched along with Bone Diseases in 15 studies
Bone Diseases: Diseases of BONES.
Excerpt | Relevance | Reference |
---|---|---|
" Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance." | 8.85 | Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009) |
"Hypogonadism was first described in the setting of advanced AIDS and can be primary or secondary." | 6.47 | Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. ( Cotter, AG; Powderly, WG, 2011) |
" Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance." | 4.85 | Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009) |
" Here, we established a rat model with secondary hyperparathyroidism (SHPT) and bone disease induced by adenine and a high phosphorous diet and analyzed the skeletal characteristics." | 3.88 | A rat model of SHPT with bone abnormalities in CKD induced by adenine and a high phosphorus diet. ( Chen, Q; Liu, BC; Lv, LL; Ni, HF; Ni, LH; Song, KY; Tang, RN; Wang, B; Wang, FM; Wang, LT; Wu, M, 2018) |
"Hypogonadism was first described in the setting of advanced AIDS and can be primary or secondary." | 2.47 | Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. ( Cotter, AG; Powderly, WG, 2011) |
" The granule form carries a risk of dosing errors and has a particularly strong, unpleasant taste." | 1.40 | Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys. ( , 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (20.00) | 29.6817 |
2010's | 11 (73.33) | 24.3611 |
2020's | 1 (6.67) | 2.80 |
Authors | Studies |
---|---|
Sato, H | 3 |
Goto, M | 3 |
Nishimura, G | 3 |
Morimoto, N | 3 |
Tokushima, H | 3 |
Horii, Y | 3 |
Takahashi, N | 3 |
Diwan, V | 1 |
Brown, L | 1 |
Gobe, GC | 1 |
Ni, LH | 1 |
Tang, RN | 1 |
Lv, LL | 1 |
Wu, M | 1 |
Wang, B | 1 |
Wang, FM | 1 |
Ni, HF | 1 |
Song, KY | 1 |
Wang, LT | 1 |
Chen, Q | 1 |
Liu, BC | 1 |
Ichchou, L | 1 |
Rist, S | 1 |
Lespessailles, E | 1 |
PriƩ, D | 1 |
Benhamou, CL | 1 |
Puthanakit, T | 1 |
Siberry, GK | 1 |
Mangioni, D | 1 |
Bandera, A | 1 |
Muscatello, A | 1 |
Squillace, N | 1 |
Crivellaro, C | 1 |
Guerra, L | 1 |
Messa, C | 1 |
Gori, A | 1 |
Lockhart, SM | 1 |
Drevets, DA | 1 |
Maggi, P | 1 |
Montinaro, V | 1 |
Leone, A | 1 |
Fasano, M | 1 |
Volpe, A | 1 |
Bellacosa, C | 1 |
Grattagliano, V | 1 |
Coladonato, L | 1 |
Lapadula, G | 1 |
Santantonio, T | 1 |
Angarano, G | 1 |
Gervasoni, C | 1 |
Minisci, D | 1 |
Meraviglia, P | 1 |
Baldelli, S | 1 |
Clementi, E | 1 |
Rizzardini, G | 1 |
Cattaneo, D | 1 |
Foster, C | 1 |
Lyall, H | 1 |
Olmscheid, B | 1 |
Pearce, G | 1 |
Zhang, S | 1 |
Gibb, DM | 1 |
Carr, A | 1 |
Hoy, J | 1 |
Cotter, AG | 1 |
Powderly, WG | 1 |
Brim, NM | 1 |
Cu-Uvin, S | 1 |
Hu, SL | 1 |
O'Bell, JW | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)[NCT01066858] | 1,765 participants (Actual) | Observational | 2011-03-22 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
4 reviews available for adenine and Bone Diseases
Article | Year |
---|---|
Adenine-induced chronic kidney disease in rats.
Topics: Adenine; Animals; Bone Diseases; Cardiovascular Diseases; Disease Models, Animal; Disease Progressio | 2018 |
Bone health in children and adolescents with perinatal HIV infection.
Topics: Adenine; Adolescent; Anti-HIV Agents; Bone Density; Bone Diseases; Child; HIV Infections; Humans; Or | 2013 |
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
Topics: Adenine; Adult; Africa South of the Sahara; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2009 |
Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Diseases; Endocrine System Dis | 2011 |
11 other studies available for adenine and Bone Diseases
Article | Year |
---|---|
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
A rat model of SHPT with bone abnormalities in CKD induced by adenine and a high phosphorus diet.
Topics: Adenine; Animals; Bone and Bones; Bone Density; Bone Diseases; Bone Diseases, Metabolic; Diet; Disea | 2018 |
Reversible increase in FGF23 in a hypophosphatemic renal and bone disease linked to antiviral therapy by adefovir.
Topics: Adenine; Aged; Antiviral Agents; Bone Diseases; Female; Fibroblast Growth Factor-23; Fibroblast Grow | 2013 |
Focal bone lesions in HIV-positive patient treated with tenofovir.
Topics: Adenine; Anti-HIV Agents; Bone Diseases; HIV Infections; Humans; Male; Middle Aged; Organophosphonat | 2014 |
Reversible bone lesions induced by tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Bone Diseases; Female; Humans; Organophosphonates; Radionuclide Imaging; Tenofovir | 2014 |
Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys.
Topics: Adenine; Anti-HIV Agents; Bone Diseases; Child; Dose-Response Relationship, Drug; HIV Infections; Hu | 2014 |
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study.
Topics: Adenine; Adult; Aged; Antiviral Agents; Bone Diseases; Drug-Related Side Effects and Adverse Reactio | 2015 |
Determinants of bone diseases in tenofovir-treated HIV patients.
Topics: Adenine; Anti-HIV Agents; Bone Diseases; HIV Infections; Humans; Tenofovir | 2016 |
Tenofovir: new indication. In chronic hepatitis B: beware bone toxicity.
Topics: Adenine; Antiviral Agents; Bone and Bones; Bone Diseases; Double-Blind Method; Drug Approval; Europe | 2009 |
Low bone mineral density with tenofovir: does statistically significant mean clinically significant?
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Bone Diseases; Female; Fractures, Bone; HIV Infection | 2010 |
Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Diseases; Fanconi Syndrome; Fe | 2007 |